AbbVie Inc. (ABBV) — 155.34 (-1.72)
Key Metrics & Ratings
- symbol ABBV
- Rev/Share 31.2388
- Book/Share 6.8519
- PB 24.4456
- Debt/Equity 5.0228
- CurrentRatio 0.9555
- ROIC 0.1685
- MktCap 295727950000.0
- FreeCF/Share 14.0104
- PFCF 11.9588
- PE 45.3861
- Debt/Assets 0.4459
- DivYield 0.0358
- ROE 0.4696
- Rating S-
- Score 5.0
- Recommendation Strong Buy
- P/E Score 5.0
- DCF Score 5.0
- P/B Score 5.0
- D/E Score 5.0
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | ABBV | Cantor Fitzgerald | -- | Overweight | -- | $200 | May 17, 2024 |
| Upgrade | ABBV | William Blair | Market Perform | Outperform | -- | -- | Jan. 29, 2024 |
| Downgrade | ABBV | HSBC Securities | Buy | Hold | -- | -- | Dec. 18, 2023 |
| Upgrade | ABBV | Goldman | Neutral | Buy | -- | -- | Dec. 11, 2023 |
| Initiation | ABBV | Deutsche Bank | -- | Hold | -- | $150 | Nov. 9, 2023 |
News
AbbVie Showcases Robust Solid Tumor Pipeline at ASCO 2024 with New Data from Its Innovative Antibody-Drug Conjugate (ADC) Platform
Published: May 28, 2024 by: PRNewsWire
Sentiment: Neutral
New safety and efficacy data in heavily pre-treated patients with metastatic colorectal cancer (CRC), from a Phase 1 study of ABBV-400, a next-generation, potential best-in-class c-Met directed ADC. Data from a first-in-human study of ABBV-706, a potential best-in-class SEZ6 directed ADC, in small cell lung cancer (SCLC), high-grade central nervous system (CNS) tumors and high-grade neuroendocrine neoplasms (NENs).
Read More
7 Biotech Stocks to Put on Your Breakthrough Radar
Published: May 27, 2024 by: InvestorPlace
Sentiment: Positive
For those seeking to decipher best speculative opportunities in the market, biotech stocks with breakthrough potential may offer plenty of firepower. Let's get some of the bad stuff out of the way first.
Read More
Forget Nvidia, Buy This Magnificent Healthcare Stock Instead
Published: May 26, 2024 by: The Motley Fool
Sentiment: Neutral
Nvidia's high valuation could make the stock vulnerable to a sell-off if the company fall short of expectations. AbbVie is a top healthcare company with underrated growth prospects.
Read More
High Yields And Low Multiples - 3 Of My Favorite Dividend Stocks To Buy Right Now
Published: May 24, 2024 by: Seeking Alpha
Sentiment: Positive
JPMorgan CEO Jamie Dimon expressed concern about inflation and predicts higher interest rates for longer than expected. He highlighted secular drivers such as the energy transition, geopolitical issues, infrastructure spending, and large deficits/debt levels. The favorable period for inflation in developed nations from 2009 to 2021 is likely over.
Read More
Why AbbVie (ABBV) is a Top Value Stock for the Long-Term
Published: May 23, 2024 by: Zacks Investment Research
Sentiment: Positive
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Read More
A Must-Own Stock for Any Portfolio
Published: May 22, 2024 by: The Motley Fool
Sentiment: Positive
This company offers growth, high yield, and dividend growth.
Read More
2 Billion More Reasons to Buy AbbVie Stock
Published: May 22, 2024 by: The Motley Fool
Sentiment: Positive
AbbVie is bolstering its psychiatry pipeline with an acquisition. The biotech it's acquiring is developing psychedelic-adjacent drugs.
Read More
3 S&P 500 Stocks That Have Proven Themselves Recession-Proof
Published: May 20, 2024 by: InvestorPlace
Sentiment: Positive
Since 1928, there have been 25 bear markets, or declines in the S&P 500 of 20% or more, according to Yardeni Research. Market corrections have been far more common.
Read More
1 Wall Street Analyst Thinks AbbVie Stock Is Going to $200. Is It a Buy at Around $165?
Published: May 20, 2024 by: The Motley Fool
Sentiment: Negative
AbbVie's lead drug Humira lost its patent-protected market exclusivity in the U.S. last year. Despite shrinking Humira revenues, AbbVie's first-quarter sales grew thanks to more recently launched blockbusters.
Read More
AbbVie Presents New Data Supporting Leading Gastroenterology Portfolio at 2024 Digestive Disease Week®
Published: May 17, 2024 by: PRNewsWire
Sentiment: Neutral
- AbbVie will present 15 abstracts, including three oral presentations, in Crohn's disease and ulcerative colitis reinforcing AbbVie's commitment to advancing the standards of care in inflammatory bowel diseases (IBD) - Data to be presented from the SEQUENCE head-to-head trial comparing risankizumab (SKYRIZI®) versus ustekinumab (STELARA®) in Crohn's disease include an economic analysis and oral presentation that assessed inflammation biomarkers - Additional presentations include efficacy and safety data evaluating clinical, endoscopic, and histologic outcomes from both the INSPIRE Phase 3 induction study and the COMMAND Phase 3 maintenance study of risankizumab as a therapy for adults with moderately to severely …
Read More
Are You Looking for a High-Growth Dividend Stock?
Published: May 16, 2024 by: Zacks Investment Research
Sentiment: Positive
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does AbbVie (ABBV) have what it takes?
Read More
AbbVie, Inc. (ABBV) Bank of America Health Care Conference Call Transcript
Published: May 15, 2024 by: Seeking Alpha
Sentiment: Neutral
AbbVie, Inc. (NYSE:ABBV ) Bank of America Health Care Conference Call May 15, 2024 1:40 PM ET Company Participants Robert Michael - CEO Roopal Thakkar - SVP, Chief Medical Officer, Global Therapeutics Jeffrey Stewart - COO Conference Call Participants Geoffrey Meacham - Bank of America Merrill Lynch Operator Geoffrey Meacham With me on stage is CEO, Rob Michael, currently President and COO, I guess, but soon to be. Robert Michael Soon to be, yes.
Read More
2 Fortune 100 Best Co's To Work For Are Also Good To Own
Published: May 15, 2024 by: Seeking Alpha
Sentiment: Positive
2 Fortune 100 Best Co's To Work For Are Also Good To Own
Read More
What Is the Dividend Payout for AbbVie Stock?
Published: May 13, 2024 by: The Motley Fool
Sentiment: Positive
AbbVie's best-selling product recently lost its patent protection, threatening the company's future results. The drugmaker's R&D pipeline, however, is more promising than it's getting credit for.
Read More
AbbVie and Gilgamesh Pharmaceuticals Announce Collaboration and Option-to-License Agreement to Develop Next-Generation Therapies for Psychiatric Disorders
Published: May 13, 2024 by: PRNewsWire
Sentiment: Neutral
- Collaboration to leverage AbbVie's psychiatry expertise and Gilgamesh's innovative research platform to develop next-generation neuroplastogens for the treatment of psychiatric disorders NORTH CHICAGO, Ill. and NEW YORK , May 13, 2024 /PRNewswire/ -- AbbVie (NYSE: ABBV) and Gilgamesh Pharmaceuticals today announced a collaboration and option-to-license agreement to develop next-generation therapies for psychiatric disorders.
Read More
3 Rock-Solid Dividend Stocks That Are Ideal for Retirees
Published: May 10, 2024 by: The Motley Fool
Sentiment: Positive
AbbVie is a diversified healthcare company that has been able to strengthen its portfolio via acquisitions. AT&T has faced a lot of negative press in recent years but its fundamentals remain sound.
Read More
Biotech Breakthroughs: 7 Stocks Driving the Next Wave in Healthcare
Published: May 07, 2024 by: InvestorPlace
Sentiment: Positive
Amid a challenging market environment, one of your best bets could be to target biotech stocks to buy. Yes, the sector can be volatile because much hinges on underlying breakthroughs.
Read More
AbbVie Tracking for New Highs in 2024
Published: May 07, 2024 by: MarketBeat
Sentiment: Positive
Shares of AbbVie NYSE: ABBV fell hard in the wake of its Q1 earnings report, but the dip is over. The market response to slowing Humira sales is overshadowed by strength in the non-Humira portfolio, resilient business, and a solid pipeline.
Read More
AbbVie to Present at the Bank of America Securities Healthcare Conference
Published: May 06, 2024 by: PRNewsWire
Sentiment: Neutral
NORTH CHICAGO, Ill. , May 6, 2024 /PRNewswire/ -- AbbVie (NYSE: ABBV) will participate in the Bank of America Securities Healthcare Conference on Wednesday, May 15, 2024.
Read More
AbbVie: Bulletproof Fundamentals
Published: April 12, 2024 by: Seeking Alpha
Sentiment: Positive
AbbVie is a profitability superstar with a strong track record of success, generating almost 40% in free cash flow margin. The company has a diverse portfolio of products across several promising drug markets, including an intact position in the immunology drugs market. The stock offers an attractive valuation, a solid dividend yield, and is recommended as a "Strong Buy" for long-term investors.
Read More
INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of AbbVie Inc. (ABBV) on Behalf of Investors
Published: April 12, 2024 by: Business Wire
Sentiment: Neutral
BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces an investigation on behalf of AbbVie Inc. (“AbbVie” or the “Company”) (NYSE: ABBV) investors concerning the Company's possible violations of federal securities laws. On April 4, 2024, AbbVie disclosed that its prior financial guidance excluded the impact of acquired In-Process Research and Development (“IPR&D”) and milestone expense. The Company also disclosed that its earnings for the first quarter of 2024 “are expect.
Read More
AbbVie: Despite The Run, Shares Still Look Attractive, Yielding 3.67%
Published: April 12, 2024 by: Seeking Alpha
Sentiment: Positive
AbbVie's stock has outperformed the market over the past decade, with a 248.90% appreciation. Despite losing patent protection for Humira, which accounted for 37% of revenue in 2022, AbbVie remains undervalued and continues to grow its dividend. AbbVie's recent acquisitions and robust pipeline position the company for future growth and expansion.
Read More
AbbVie Announces Late-Breaking Data at AAN Supporting Long-Term Safety and Efficacy of Atogepant (QULIPTA®) for Preventive Treatment of Migraine
Published: April 12, 2024 by: PRNewsWire
Sentiment: Neutral
- Interim analysis of an ongoing 156-week extension study supports long-term safety, tolerability and efficacy of atogepant 60 mg to prevent chronic and episodic migraine - Seventy percent of subjects achieved ≥50% reduction in monthly migraine days at Weeks 13-16 and this was consistent during the 48 weeks of open-label treatment - Findings will be showcased in an oral presentation at the American Academy of Neurology (AAN) Annual Meeting Scientific Platform Session for Emerging Science NORTH CHICAGO, Ill. , April 12, 2024 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced an interim analysis of an ongoing Phase 3, open-label 156-week extension …
Read More
AbbVie (ABBV) Stock Declines While Market Improves: Some Information for Investors
Published: April 11, 2024 by: Zacks Investment Research
Sentiment: Neutral
The latest trading day saw AbbVie (ABBV) settling at $167.52, representing a -0.89% change from its previous close.
Read More
Wall Street Favorites: 3 Biotech Stocks With Strong Buy Ratings for April 2024
Published: April 11, 2024 by: InvestorPlace
Sentiment: Positive
Biotech stocks were among the worst performers in 2023. And so far in 2024, investors are still waiting on the recovery rally.
Read More
The Law Offices of Frank R. Cruz Announces Investigation of AbbVie Inc. (ABBV) on Behalf of Investors
Published: April 10, 2024 by: Business Wire
Sentiment: Neutral
LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz announces an investigation of AbbVie Inc. (“AbbVie” or the “Company”) (NYSE: ABBV) on behalf of investors concerning the Company's possible violations of federal securities laws. If you are a shareholder who suffered a loss, click here to participate. On April 4, 2024, AbbVie disclosed that its prior financial guidance excluded the impact of acquired In-Process Research and Development (“IPR&D”) and milestone expense. The Compan.
Read More
Are You Looking for a High-Growth Dividend Stock?
Published: April 10, 2024 by: Zacks Investment Research
Sentiment: Positive
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does AbbVie (ABBV) have what it takes?
Read More
3 Dividend Growth Stocks With Yields Above 3% That You Can Buy and Hold for the Next Decade
Published: April 09, 2024 by: The Motley Fool
Sentiment: Positive
AbbVie's dividend payout has more than tripled over the past decade, and it could soar much further in the decade ahead. Bristol Myers Squibb offers a juicy 4.7% dividend yield at recent prices.
Read More
Passive Income Perfection: 7 Dividend Stocks to Generate $50,000 Per Year
Published: April 04, 2024 by: InvestorPlace
Sentiment: Positive
The topic of passive income is popular these days. Investors, consumers, and many other individuals are curious about any method that can produce income without work.
Read More
The 3 Best Stocks to Buy in April 2024
Published: April 02, 2024 by: InvestorPlace
Sentiment: Positive
The big money might be feeling a bit queasy about overexposure to risk-on assets, presenting a framework to follow regarding the best stocks to buy in April. As I've mentioned many times before, technology-related securities saw an outflow recently of $4.4 billion.
Read More
About AbbVie Inc. (ABBV)
- IPO Date 2013-01-02
- Website https://www.abbvie.com
- Industry Drug Manufacturers - General
- CEO Mr. Richard A. Gonzalez
- Employees 50000